TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03883581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan HBr and quinidine sulfate
Description: All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
Study: NCT01919944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686
Description: capsules containing either 10 mg or 50 mg VLY-686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686
Description: capsules containing either 10 mg or 50 mg VLY-686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686
Description: capsules containing either 10 mg or 50 mg VLY-686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
Study: NCT04562181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bispectral index and qCON/qNOX monitoring
Description: This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
Study: NCT00877240

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff
Description: the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
Study: NCT02362321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
Study: NCT03951077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally
Study: NCT00852033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Based Intervention plus booster
Description: The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined brief motivational intervention and parent based intervention plus boosters for both interventions
Description: A combination of Intervention 1 and 2.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Assessment only
Description: No intervention, assessment only.
Study: NCT03299998

Intervention type: PROCEDURE
Intervention: Maxillary and mandibular blocks
Description: A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
Study: NCT02982460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoinertial + eccentric exercise
Description: A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: A session of eccentric exercise covers the strength of scapular muscles.
Study: NCT04973501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual physiotherapeutic correction (MFK) Method
Description: Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization (DNS) Method
Description: Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
Study: NCT02366468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Description: intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.5 mg
Description: intravitreal injection
Study: NCT03584542

Intervention type: OTHER
Intervention: No interventional study
Description: No Interventional study - Only one questionnaire will be done for patients and for general practitioners

Intervention type: OTHER
Intervention: No interventional study
Description: No Interventional study - Only one questionnaire will be done for patients and for general practitioners

Intervention type: OTHER
Intervention: No interventional study
Description: No Interventional study - Only one questionnaire will be done for patients and for general practitioners
Study: NCT05212805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented upper-limb training
Description: The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented upper-limb training
Description: The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sport events participation
Description: A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
Study: NCT04209959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifekalant
Description: Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifekalant
Description: Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifekalant
Description: Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
Study: NCT00030498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01008319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Study: NCT03951077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered orally
Study: NCT03636217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-Milk Breakfast
Description: This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-Kefir Breakfast
Description: In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HGI-Kefir Breakfast
Description: In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
Study: NCT01687361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branched-chain amino acids (BCAA) supplementation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT01756768

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]-PD-0332991
Description: A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
Study: NCT01507519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Coronary Stent System (Biomime)
Description: Coronary Artey PTCA
Study: NCT01183234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD544
Description: two 30mg capsules, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Description: one 60mg capsule, single oral dose
Study: NCT03084341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Elongation
Description: Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
Study: NCT00791388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule, 2x/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 50 mg, 2x/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 100mg, 2x/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 200 mg, 2x/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 400 mg, 2x/day for 14 days
Study: NCT03431441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Marketed Contact Lens
Description: Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
Study: NCT02043938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SedLine EEG sensor
Description: Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
Study: NCT03084341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
Study: NCT02415673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed orthodontics appliance and arch wire
Description: Two nickel-titanium alignment and leveling sequences were employed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed orthodontics appliance and arch wire
Description: Two nickel-titanium alignment and leveling sequences were employed
Study: NCT04735328

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LOCI
Description: LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
Study: NCT02471235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Pulmonary rehabilitation
Study: NCT05005663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical management of incisional hernia
Description: surgical repair of the incisional hernia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical management of incisional hernia
Description: surgical repair of the incisional hernia
Study: NCT02222558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study: NCT02305771

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalography

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT03520985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients \> 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression.
Study: NCT05288647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ injection
Description: four sodium hyaluronate injections in superior TMJ space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ injection
Description: four sodium hyaluronate injections in superior TMJ space